Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hybrid ImmunoTherapy (ATG/Dexamethasone/Etoposide) for Hemophagocytic LymphoHistiocytosis
NCT01104025Phase 2Completed
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Apr 2010
- Primary completion
- Nov 2015
- Modality
- Recombinant Proteins and Enzymes, Orthosteric Ligands, Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of antithymocyte globulin rabbit, dexamethasone and etoposide in hemophagocytic lymphohistiocytosis (HLH), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoint: Overall Survival at 8 weeks. Started Apr 2010; status: completed.
02
Drugs
antithymocyte globulin rabbitdexamethasoneetoposide
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)
Beyond the preview
Go deeper on NCT01104025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01104025.